Accessibility Menu
Bioasis Technologies logo

Bioasis Technologies(OTC) BIOAF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-100%
1 Year-75%
1 Month+9,900%
$0.00
+0.00%
+0.00Today
Bioasis Technologies last closing stock price
MetricPriceDate
Last closeUSD 0.002026-04-13
Bioasis Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9,900%USD 0.002025-11-10
1 month+9,900%USD 0.002025-11-10
3 month+9,900%USD 0.002025-11-10
Year to date+9,900%USD 0.002025-11-10
1 year-75%USD 0.002025-02-27
3 year-99.44%USD 0.022023-04-14
5 year-99.97%USD 0.312021-04-14
Since inception-99.99%USD 1.312012-05-04

Bioasis Technologies Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$269.38K

Net Income (TTM)

-CA$2.88M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

2.63 (High)

Price

$0.00

Volume

74,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 3, 2026

BIOAF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bioasis Technologies

Bioasis Technologies Inc. is a biopharmaceutical company focused on developing innovative treatments and diagnostic tools for neurological conditions. The company utilizes its proprietary xB3 platform to effectively deliver therapeutic agents across the blood-brain barrier, targeting various central nervous system disorders.

Products and Services
  • xB3-001 for treating brain metastases
  • xB3-002 focused on glioblastoma treatment
  • xB3-007 targeting neurodegenerative diseases
Growth Outlook
  • Strategic partnerships with leading firms enhance research capabilities
  • Focus on CNS disorders positions Bioasis in a growing market
  • Innovative xB3 platform offers potential for significant breakthroughs
Financial Highlights
  • Recent quarterly revenue of 148,936 CAD, up from 120,440 CAD
  • Trailing twelve months (TTM) net income margin of -78.46%
  • Cash and cash equivalents decreased to 156,515 CAD in Q3 2022
Bioasis Technologies Inc. is dedicated to addressing unmet medical needs in the field of neurology. The xB3 platform is a key differentiator, enabling the company to explore treatments for complex conditions that have limited therapeutic options. The recent increase in quarterly revenue indicates a positive trend in the company's operational performance, despite ongoing challenges reflected in the net income margin. The strategic alliances with established firms further bolster the company's research and development efforts, potentially leading to innovative solutions in the biopharmaceutical landscape. As the market for CNS disorders continues to expand, Bioasis is well-positioned to capitalize on emerging opportunities.
AI Generated • Aug 14, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Deborah A. Rathjen, PhD

Website

www.bioasis.us

Headquarters

New Haven, CT 06510, US

BIOAF Financials

Key Financial Metrics (TTM)

Gross Margin

-45.57%

Operating Margin

-12956.07%

Net Income Margin

-7846.50%

Return on Equity

392.02%

Return on Capital

N/A

Return on Assets

-130.64%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

74.00K

Avg. Volume

0

Financials (TTM)

Gross Profit

-CA$9.96K

Operating Income

-CA$4.36M

EBITDA

-CA$3.05M

Operating Cash Flow

-CA$1.94M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$1.94M

Cash & ST Invst.

CA$156.52K

Total Debt

CA$2.21M

Bioasis Technologies Performance Analysis

Bioasis Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-02-28CAD 30,105N/A
Bioasis Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-02-28-100.0%
Q12022-05-31N/A
Q22022-08-31N/A
Q32022-11-3023.7%
Bioasis Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-02-28CAD -0.03N/A
Bioasis Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-02-2855.7%
Q12022-05-3159.0%
Q22022-08-31-334.4%
Q32022-11-309.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

CA$148.94K

+294.8%

Gross Profit

-CA$71.92K

-290.6%

Gross Margin

-48.29%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

4

N/A

Net Income

-CA$985.67K

+22.5%

EBITDA

-CA$664.03K

+12.9%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

CA$156.52K

-94.0%

Total Debt

CA$2.21M

+9.5%

Accounts Receivable

CA$13.85K

-77.1%

Inventory

CA$0.00

N/A

Long Term Debt

CA$713.59K

+37.1%

Short Term Debt

CA$1.50M

+0.0%

Return on Assets

-1.31%

N/A

Return on Invested Capital

6.76%

N/A

Free Cash Flow

-CA$443.31K

+53.1%

Operating Cash Flow

-CA$443.31K

+53.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IRBSIR Biosciences Holdings Inc.
$0.00+0.00%
EMYSFEasy Technologies Inc.
$0.02+0.00%
TOMDFTodos Medical Ltd.
$0.00+0.00%
NVNOenVVeno Medical Corporation
$10.99+1.24%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About BIOAF

What is the current price of Bioasis Technologies?

Bioasis Technologies is trading at $0.00 per share.

What is the 52-week range for Bioasis Technologies?

Over the past 52 weeks, Bioasis Technologies has traded between $0.00 and $0.00.

How much debt does Bioasis Technologies have?

As of the most recent reporting period, Bioasis Technologies reported total debt of CA$1.50M.

How much cash does Bioasis Technologies have on hand?

Bioasis Technologies reported CA$1.36M in cash and cash equivalents in its most recent financial results.

What is Bioasis Technologies’s dividend yield?

Bioasis Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services